1
|
De Cock L, Bercier V, Van Den Bosch L. New developments in pre-clinical models of ALS to guide translation. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2024; 176:477-524. [PMID: 38802181 DOI: 10.1016/bs.irn.2024.04.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2024]
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder in which selective death of motor neurons leads to muscle weakness and paralysis. Most research has focused on understanding and treating monogenic familial forms, most frequently caused by mutations in SOD1, FUS, TARDBP and C9orf72, although ALS is mostly sporadic and without a clear genetic cause. Rodent models have been developed to study monogenic ALS, but despite numerous pre-clinical studies and clinical trials, few disease-modifying therapies are available. ALS is a heterogeneous disease with complex underlying mechanisms where several genes and molecular pathways appear to play a role. One reason for the high failure rate of clinical translation from the current models could be oversimplification in pre-clinical studies. Here, we review advances in pre-clinical models to better capture the heterogeneous nature of ALS and discuss the value of novel model systems to guide translation and aid in the development of precision medicine.
Collapse
Affiliation(s)
- Lenja De Cock
- Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Louvain-University of Leuven, Leuven, Belgium; Center for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgium
| | - Valérie Bercier
- Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Louvain-University of Leuven, Leuven, Belgium; Center for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgium
| | - Ludo Van Den Bosch
- Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI), KU Louvain-University of Leuven, Leuven, Belgium; Center for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgium.
| |
Collapse
|
2
|
Adedara IA, Atanda OE, Sant'Anna Monteiro C, Rosemberg DB, Aschner M, Farombi EO, Rocha JBT, Furian AF, Emanuelli T. Cellular and molecular mechanisms of aflatoxin B 1-mediated neurotoxicity: The therapeutic role of natural bioactive compounds. ENVIRONMENTAL RESEARCH 2023; 237:116869. [PMID: 37567382 DOI: 10.1016/j.envres.2023.116869] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 08/05/2023] [Accepted: 08/08/2023] [Indexed: 08/13/2023]
Abstract
Aflatoxin B1 (AFB1), a dietary toxin from the mold Aspergillus species, is well acknowledged to elicit extra-hepatic toxicity in both animals and humans. The neurotoxicity of AFB1 has become a global public health concern. Contemporary research on how AFB1 enters the brain to elicit neuronal dysregulation leading to noxious neurological outcomes has increased greatly in recent years. The current review discusses several neurotoxic outcomes and susceptible targets of AFB1 toxicity at cellular, molecular and genetic levels. Specifically, neurotoxicity studies involving the use of brain homogenates, neuroblastoma cell line IMR-32, human brain microvascular endothelial cells, microglial cells, and astrocytes, as well as mammalian and non-mammalian models to unravel the mechanisms associated with AFB1 exposure are highlighted. Further, some naturally occurring bioactive compounds with compelling therapeutic effects on AFB1-induced neurotoxicity are reviewed. In conclusion, available data from literature highlight AFB1 as a neurotoxin and its possible pathological contribution to neurological disorders. Further mechanistic studies aimed at discovering and developing effective therapeutics for AFB1 neurotoxicity is warranted.
Collapse
Affiliation(s)
- Isaac A Adedara
- Department of Food Science and Technology, Center of Rural Sciences, Federal University of Santa Maria, Camobi, 97105-900 Santa Maria, RS, Brazil; Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria.
| | - Oluwadarasimi E Atanda
- Human Toxicology Program, Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, 52242, USA
| | - Camila Sant'Anna Monteiro
- Department of Food Science and Technology, Center of Rural Sciences, Federal University of Santa Maria, Camobi, 97105-900 Santa Maria, RS, Brazil
| | - Denis B Rosemberg
- Laboratory of Experimental Neuropsychobiology, Department of Biochemistry and Molecular Biology, Federal University of Santa Maria, Camobi, 97105-900 Santa Maria, RS, Brazil
| | - Michael Aschner
- Department of Molecular Pharmacology; Albert Einstein College of Medicine Forchheimer 209; 1300 Morris Park Avenue, Bronx, NY 10461, USA
| | - Ebenezer O Farombi
- Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria
| | - Joao B T Rocha
- Department of Biochemical and Molecular Biology, Federal University of Santa Maria, 97105-900, Santa Maria, RS, Brazil
| | - Ana Flávia Furian
- Department of Food Science and Technology, Center of Rural Sciences, Federal University of Santa Maria, Camobi, 97105-900 Santa Maria, RS, Brazil
| | - Tatiana Emanuelli
- Department of Food Science and Technology, Center of Rural Sciences, Federal University of Santa Maria, Camobi, 97105-900 Santa Maria, RS, Brazil
| |
Collapse
|
3
|
Sarasamma S, Karim A, Orengo JP. Zebrafish Models of Rare Neurological Diseases like Spinocerebellar Ataxias (SCAs): Advantages and Limitations. BIOLOGY 2023; 12:1322. [PMID: 37887032 PMCID: PMC10604122 DOI: 10.3390/biology12101322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 09/28/2023] [Accepted: 10/06/2023] [Indexed: 10/28/2023]
Abstract
Spinocerebellar ataxia (SCA) is a heterogeneous group of rare familial neurodegenerative disorders that share the key feature of cerebellar ataxia. Clinical heterogeneity, diverse gene mutations and complex neuropathology pose significant challenges for developing effective disease-modifying therapies in SCAs. Without a deep understanding of the molecular mechanisms involved for each SCA, we cannot succeed in developing targeted therapies. Animal models are our best tool to address these issues and several have been generated to study the pathological conditions of SCAs. Among them, zebrafish (Danio rerio) models are emerging as a powerful tool for in vivo study of SCAs, as well as rapid drug screens. In this review, we will summarize recent progress in using zebrafish to study the pathology of SCAs. We will discuss recent advancements on how zebrafish models can further clarify underlying genetic, neuroanatomical, and behavioral pathogenic mechanisms of disease. We highlight their usefulness in rapid drug discovery and large screens. Finally, we will discuss the advantages and limitations of this in vivo model to develop tailored therapeutic strategies for SCA.
Collapse
Affiliation(s)
- Sreeja Sarasamma
- Departments of Neurology and Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA
- Department of Fisheries and Wildlife, Michigan State University, East Lansing, MI 48824, USA
| | - Anwarul Karim
- School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - James P. Orengo
- Departments of Neurology and Neuroscience, Baylor College of Medicine, Houston, TX 77030, USA
| |
Collapse
|
4
|
Wu X, Hua X, Xu K, Song Y, Lv T. Zebrafish in Lung Cancer Research. Cancers (Basel) 2023; 15:4721. [PMID: 37835415 PMCID: PMC10571557 DOI: 10.3390/cancers15194721] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 09/19/2023] [Accepted: 09/22/2023] [Indexed: 10/15/2023] Open
Abstract
Zebrafish is increasingly used as a model organism for cancer research because of its genetic and physiological similarities to humans. Modeling lung cancer (LC) in zebrafish has received significant attention. This review focuses on the insights gained from using zebrafish in LC research. These insights range from investigating the genetic and molecular mechanisms that contribute to the development and progression of LC to identifying potential drug targets, testing the efficacy and toxicity of new therapies, and applying zebrafish for personalized medicine studies. This review provides a comprehensive overview of the current state of LC research performed using zebrafish, highlights the advantages and limitations of this model organism, and discusses future directions in the field.
Collapse
Affiliation(s)
- Xiaodi Wu
- Department of Clinical Medicine, Medical School of Nanjing University, Nanjing 210093, China; (X.W.); (K.X.)
| | - Xin Hua
- Department of Clinical Medicine, Southeast University Medical College, Nanjing 210096, China;
| | - Ke Xu
- Department of Clinical Medicine, Medical School of Nanjing University, Nanjing 210093, China; (X.W.); (K.X.)
| | - Yong Song
- Department of Clinical Medicine, Southeast University Medical College, Nanjing 210096, China;
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China
| | - Tangfeng Lv
- Department of Clinical Medicine, Medical School of Nanjing University, Nanjing 210093, China; (X.W.); (K.X.)
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China
| |
Collapse
|
5
|
Zebrafish as a Potential Model for Neurodegenerative Diseases: A Focus on Toxic Metals Implications. Int J Mol Sci 2023; 24:ijms24043428. [PMID: 36834835 PMCID: PMC9959844 DOI: 10.3390/ijms24043428] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 01/31/2023] [Accepted: 02/05/2023] [Indexed: 02/11/2023] Open
Abstract
In the last century, industrial activities increased and caused multiple health problems for humans and animals. At this moment, heavy metals are considered the most harmful substances for their effects on organisms and humans. The impact of these toxic metals, which have no biological role, poses a considerable threat and is associated with several health problems. Heavy metals can interfere with metabolic processes and can sometimes act as pseudo-elements. The zebrafish is an animal model progressively used to expose the toxic effects of diverse compounds and to find treatments for different devastating diseases that human beings are currently facing. This review aims to analyse and discuss the value of zebrafish as animal models used in neurological conditions, such as Alzheimer's disease (AD), and Parkinson's disease (PD), particularly in terms of the benefits of animal models and the limitations that exist.
Collapse
|
6
|
Menegola E, Battistoni M, Metruccio F, Di Renzo F. Advantages and disadvantages of the use of Xenopus laevis embryos and Zebra fish as alternative methods to assess teratogens. CURRENT OPINION IN TOXICOLOGY 2023. [DOI: 10.1016/j.cotox.2023.100387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
|
7
|
Hopkins CE, Brock T, Caulfield TR, Bainbridge M. Phenotypic screening models for rapid diagnosis of genetic variants and discovery of personalized therapeutics. Mol Aspects Med 2022; 91:101153. [PMID: 36411139 PMCID: PMC10073243 DOI: 10.1016/j.mam.2022.101153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 10/22/2022] [Accepted: 10/23/2022] [Indexed: 11/19/2022]
Abstract
Precision medicine strives for highly individualized treatments for disease under the notion that each individual's unique genetic makeup and environmental exposures imprints upon them not only a disposition to illness, but also an optimal therapeutic approach. In the realm of rare disorders, genetic predisposition is often the predominant mechanism driving disease presentation. For such, mostly, monogenic disorders, a causal gene to phenotype association is likely. As a result, it becomes important to query the patient's genome for the presence of pathogenic variations that are likely to cause the disease. Determining whether a variant is pathogenic or not is critical to these analyses and can be challenging, as many disease-causing variants are novel and, ergo, have no available functional data to help categorize them. This problem is exacerbated by the need for rapid evaluation of pathogenicity, since many genetic diseases present in young children who will experience increased morbidity and mortality without rapid diagnosis and therapeutics. Here, we discuss the utility of animal models, with a focus mainly on C. elegans, as a contrast to tissue culture and in silico approaches, with emphasis on how these systems are used in determining pathogenicity of variants with uncertain significance and then used to screen for novel therapeutics.
Collapse
Affiliation(s)
| | | | - Thomas R Caulfield
- Mayo Clinic, Department of Neuroscience, Department of Computational Biology, Department of Clinical Genomics, Jacksonville, FL, 32224, Rochester, MN, 55905, USA
| | | |
Collapse
|
8
|
Charlie-Silva I, Feitosa NM, Pontes LG, Fernandes BH, Nóbrega RH, Gomes JMM, Prata MNL, Ferraris FK, Melo DC, Conde G, Rodrigues LF, Aracati MF, Corrêa-Junior JD, Manrique WG, Superio J, Garcez AS, Conceição K, Yoshimura TM, Núñez SC, Eto SF, Fernandes DC, Freitas AZ, Ribeiro MS, Nedoluzhko A, Lopes-Ferreira M, Borra RC, Barcellos LJG, Perez AC, Malafaia G, Cunha TM, Belo MAA, Galindo-Villegas J. Plasma proteome responses in zebrafish following λ-carrageenan-Induced inflammation are mediated by PMN leukocytes and correlate highly with their human counterparts. Front Immunol 2022; 13:1019201. [PMID: 36248846 PMCID: PMC9559376 DOI: 10.3389/fimmu.2022.1019201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Accepted: 09/09/2022] [Indexed: 11/23/2022] Open
Abstract
Regulation of inflammation is a critical process for maintaining physiological homeostasis. The λ-carrageenan (λ-CGN) is a mucopolysaccharide extracted from the cell wall of red algae (Chondrus crispus) capable of inducing acute intestinal inflammation, which is translated into the production of acute phase reactants secreted into the blood circulation. However, the associated mechanisms in vertebrates are not well understood. Here, we investigated the crucial factors behind the inflammatory milieu of λ-CGN-mediated inflammation administered at 0, 1.75, and 3.5% (v/w) by i.p. injection into the peritoneal cavity of adult zebrafish (ZF) (Danio rerio). We found that polymorphonuclear leukocytes (neutrophils) and lymphocytes infiltrating the ZF peritoneal cavity had short-term persistence. Nevertheless, they generate a strong pattern of inflammation that affects systemically and is enough to produce edema in the cavity. Consistent with these findings, cell infiltration, which causes notable tissue changes, resulted in the overexpression of several acute inflammatory markers at the protein level. Using reversed-phase high-performance liquid chromatography followed by a hybrid linear ion-trap mass spectrometry shotgun proteomic approach, we identified 2938 plasma proteins among the animals injected with PBS and 3.5% λ-CGN. First, the bioinformatic analysis revealed the composition of the plasma proteome. Interestingly, 72 commonly expressed proteins were recorded among the treated and control groups, but, surprisingly, 2830 novel proteins were differentially expressed exclusively in the λ-CGN-induced group. Furthermore, from the commonly expressed proteins, compared to the control group 62 proteins got a significant (p < 0.05) upregulation in the λ-CGN-treated group, while the remaining ten proteins were downregulated. Next, we obtained the major protein-protein interaction networks between hub protein clusters in the blood plasma of the λ-CGN induced group. Moreover, to understand the molecular underpinnings of these effects based on the unveiled protein sets, we performed a bioinformatic structural similarity analysis and generated overlapping 3D reconstructions between ZF and humans during acute inflammation. Biological pathway analysis pointed to the activation and abundance of diverse classical immune and acute phase reactants, several catalytic enzymes, and varied proteins supporting the immune response. Together, this information can be used for testing and finding novel pharmacological targets to treat human intestinal inflammatory diseases.
Collapse
Affiliation(s)
| | - Natália M. Feitosa
- Integrated Laboratory of Translational Bioscience, Institute of Biodiversity and Sustainability, Federal University of Rio de Janeiro, Macaé, Brazil
| | | | - Bianca H. Fernandes
- Laboratório de Controle Genético e Sanitário, Faculdade de Medicina Universidade de São Paulo, São Paulo, Brazil
| | - Rafael H. Nóbrega
- Reproductive and Molecular Biology Group, Department of Morphology, Institute of Biosciences, São Paulo State University, São Paulo, Brazil
| | - Juliana M. M. Gomes
- Transplantation Immunobiology Lab, Department of Immunology, Institute of Biomedical Sciences, Universidade de São Paulo, São Paulo, Brazil
| | - Mariana N. L. Prata
- Department of Pharmacology, Instituto de CiênciasBiomédicas-Universidade Federal de Minas Gerais (ICB-UFMG), Belo Horizonte, Brazil
| | - Fausto K. Ferraris
- Department of Pharmacology and Toxicology, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil
| | - Daniela C. Melo
- Laboratory of Zebrafish from Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
| | - Gabriel Conde
- Department of Preventive Veterinary Medicine, São Paulo State University, São Paulo, Brazil
| | - Letícia F. Rodrigues
- Department of Preventive Veterinary Medicine, São Paulo State University, São Paulo, Brazil
| | - Mayumi F. Aracati
- Department of Preventive Veterinary Medicine, São Paulo State University, São Paulo, Brazil
| | - José D. Corrêa-Junior
- Department of Morphology, Instituto de CiênciasBiomédicas-Universidade Federal de Minas Gerais (ICB-UFMG), Belo Horizonte, Brazil
| | - Wilson G. Manrique
- Veterinary College, Federal University of Rondonia, Rolim de Moura, Brazil
| | - Joshua Superio
- Department of Aquaculture, Faculty of Biosciences and Aquaculture, Nord University, Bodø, Norway
| | | | - Katia Conceição
- Peptide Biochemistry Laboratory, Universidade Federal de São Paulo (UNIFESP), Sao Jose Dos Campos, Brazil
| | - Tania M. Yoshimura
- Center for Lasers and Applications, Instituto de PesquisasEnergéticas e Nucleares (IPEN-CNEN), Sao Paulo, Brazil
| | - Silvia C. Núñez
- University Brazil, São Paulo, Brazil
- University Brazil, Descalvado, Brazil
| | - Silas F. Eto
- Development and Innovation Laboratory, Center of Innovation and Development, Butantan Institute, São Paulo, Brazil
| | - Dayanne C. Fernandes
- Department of Preventive Veterinary Medicine, São Paulo State University, São Paulo, Brazil
| | - Anderson Z. Freitas
- Center for Lasers and Applications, Instituto de PesquisasEnergéticas e Nucleares (IPEN-CNEN), Sao Paulo, Brazil
| | - Martha S. Ribeiro
- Center for Lasers and Applications, Instituto de PesquisasEnergéticas e Nucleares (IPEN-CNEN), Sao Paulo, Brazil
| | - Artem Nedoluzhko
- Paleogenomics Laboratory, European University at Saint Petersburg, Saint Petersburg, Russia
| | | | - Ricardo C. Borra
- Department of Genetics and Evolution, Federal University of São Carlos, São Paulo, Brazil
| | - Leonardo J. G. Barcellos
- Postgraduate Program in Pharmacology, Federal University of Santa Maria, Rio Grande do Sul, Brazil
- Postgraduate Program in Bioexperimentation. University of Passo Fundo, Rio Grande do Sul, Brazil
| | - Andrea C. Perez
- Department of Pharmacology and Toxicology, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil
| | - Guilheme Malafaia
- Biological Research Laboratory, Goiano Federal Institute, Urutaí, Brazil
| | - Thiago M. Cunha
- Center of Research in Inflammatory Diseases, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
- Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
| | - Marco A. A. Belo
- Department of Preventive Veterinary Medicine, São Paulo State University, São Paulo, Brazil
- University Brazil, São Paulo, Brazil
- University Brazil, Descalvado, Brazil
- *Correspondence: Marco A. A. Belo, ; Jorge Galindo-Villegas,
| | - Jorge Galindo-Villegas
- Department of Genomics, Faculty of Biosciences and Aquaculture, Nord University, Bodø, Norway
- *Correspondence: Marco A. A. Belo, ; Jorge Galindo-Villegas,
| |
Collapse
|